Dual Protein Biosensor for LPA Quantification in Serum
Solution Overview
Problem
Current methods for detecting ovarian cancer, particularly in early stages, are inadequate due to the lack of reliable blood-based biomarkers, with existing biomarkers like CA-125 showing high false positives and not being effective for early stage detection, and lysophosphatidic acid (LPA) being elevated in both cancer patients and healthy individuals, making it difficult to diagnose ovarian cancer accurately.
Innovation Solution
A biosensor system using ultraviolet-visible (UV-visible) or fluorescence spectroscopy with a dual protein probe system comprising gelsolin and dye-modified actin immobilized on a solid support through a linker, allowing for rapid and label-free detection and quantification of LPA in liquid samples, including serum, to aid in early ovarian cancer diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CA-125 is used as a biomarker for ovarian cancer detection, then detection capability is provided, but false positives increase and early stage detection effectiveness decreases
Solution Approach 1:
The invention shifts from detecting CA-125 protein levels to detecting LPA metabolite levels, fundamentally changing the biomarker parameter being measured. This parameter change enables better differentiation between cancer patients and healthy individuals, particularly in early stages where CA-125 fails.
Solution Approach 2:
The invention introduces LPA as an intermediary biomarker that reflects cancer-related metabolic changes without being directly produced by tumors like CA-125. This intermediary approach provides indirect but more reliable evidence of cancer presence, reducing false positives while maintaining detection sensitivity.
2Measurement precision
If LPA detection is implemented, then potential for early detection improves, but false positives increase due to LPA elevation in healthy individuals
Solution Approach 1:
The invention focuses on detecting specific LPA metabolite profiles and patterns rather than total LPA levels alone. By analyzing the quality and distribution of different LPA species, the method can distinguish between elevation due to cancer versus normal physiological variations in healthy individuals.
Solution Approach 2:
The invention combines LPA detection with multiple analytical parameters and potentially complementary biomarkers to create a composite diagnostic approach. This multi-parameter composite method enhances diagnostic reliability by cross-validating LPA findings against other clinical and biochemical data.
3Measurement precision
If a dual protein probe system is used in the biosensor, then detection sensitivity improves, but device complexity increases
Solution Approach 1:
The invention merges two protein probes (gelsolin and actin) into a single integrated biosensor platform. The proteins work together in a coordinated manner where gelsolin binds LPA and triggers actin polymerization, creating a unified detection system that enhances sensitivity without requiring separate independent detection mechanisms.
Solution Approach 2:
The invention replaces complex mechanical or electronic detection systems with a biochemical amplification mechanism. The dual protein system uses natural biological processes (LPA binding, actin polymerization) to generate detectable signals, eliminating the need for sophisticated mechanical transducers or complex electronic signal processing while maintaining high sensitivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The biosensor system demonstrates promise in reproducibility and long-term storage, providing a viable method for detecting LPA in ovarian cancer patients with reduced false positives, potentially improving early stage detection and survival rates by accurately quantifying LPA levels in serum samples.
Implementation Method 1
A biosensor system using ultraviolet-visible (UV-visible) or fluorescence spectroscopy with a dual protein probe system comprising gelsolin and dye-modified actin
Implementation Method 2
A biosensor system using ultraviolet-visible (UV-visible) or fluorescence spectroscopy with a dual protein probe system
Data Source
AI summary
The present disclosure relates to biosensors, kits and methods for detecting and/or quantifying lysophosphatidic acid (LPA) in a liquid sample such as a serum sample from a subject. The present disclosure also relates to linker compounds that are useful, for example, in the biosensors, kits and methods of the present disclosure and to methods for preparing a biosensor for detecting and/or quantifying lysophosphatidic acid (LPA) in a liquid sample.